Brit Mollenhauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brit Mollenhauer has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Claudia Trenkwalder
10 shared publications- Jens Wiltfang
Universitätsmedizin Göttingen
4 shared publications - Michael G. Schlossmacher
Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada
4 shared publications Friederike Sixel-Döring
3 shared publicationsHermann Esselmann
Department of Psychiatry and Psychotherapy; University of Duisburg-Essen; Essen; Germany
3 shared publications- Markus Otto
Department of Neurology Martin‐Luther‐University Halle‐Wittenberg Halle (Saale) Germany
3 shared publications
Latest Publications
- Open Access
- 3 April 2019
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 8 (1) , 1-7
No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors
IgG-class autoantibodies to N-Methyl-D-Aspartate (NMDA)-type glutamate receptors define a novel entity of autoimmune encephalitis. Studies examining the prevalence of NMDA IgA/IgM antibodies in patients with Parkinson disease with/without dementia produced conflicting results. We measured NMDA antibodies in a large, well phenotyped sample of Parkinson patients without and with cognitive impairment (n = 296) and controls (n = 295) free of neuropsychiatric disease. Detailed phenotyping and large numbers allowed statistically meaningful correlation of antibody status with diagnostic subgroups as well as quantitative indicators of disease severity and cognitive impairment. NMDA antibodies were analysed in the serum of patients and controls using well established validated assays. We used anti-NMDA antibody positivity as the main independent variable and correlated it with disease status and phenotypic characteristics. The frequency of NMDA IgA/IgM antibodies was lower in Parkinson patients (13%) than in controls (22%) and higher than in previous studies in both groups. NMDA IgA/IgM antibodies were neither significantly associated with diagnostic subclasses of Parkinson disease according to cognitive impairment, nor with quantitative indicators of disease severity and cognitive impairment. A positive NMDA antibody status was positively correlated with age in controls but not in Parkinson patients. It is unlikely albeit not impossible that NMDA antibodies play a significant role in the pathogenesis or progression of Parkinson disease e.g. to Parkinson disease with dementia, while NMDA IgG antibodies define a separate disease of its own.
- 3 April 2019
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 8 (1) , 1-7
Open AccessNo association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors
IgG-class autoantibodies to N-Methyl-D-Aspartate (NMDA)-type glutamate receptors define a novel entity of autoimmune encephalitis. Studies examining the prevalence of NMDA IgA/IgM antibodies in patients with Parkinson disease with/without dementia produced conflicting results. We measured NMDA antibodies in a large, well phenotyped sample of Parkinson patients without and with cognitive impairment (n = 296) and controls (n = 295) free of neuropsychiatric disease. Detailed phenotyping and large numbers allowed statistically meaningful correlation of antibody status with diagnostic subgroups as well as quantitative indicators of disease severity and cognitive impairment. NMDA antibodies were analysed in the serum of patients and controls using well established validated assays. We used anti-NMDA antibody positivity as the main independent variable and correlated it with disease status and phenotypic characteristics. The frequency of NMDA IgA/IgM antibodies was lower in Parkinson patients (13%) than in controls (22%) and higher than in previous studies in both groups. NMDA IgA/IgM antibodies were neither significantly associated with diagnostic subclasses of Parkinson disease according to cognitive impairment, nor with quantitative indicators of disease severity and cognitive impairment. A positive NMDA antibody status was positively correlated with age in controls but not in Parkinson patients. It is unlikely albeit not impossible that NMDA antibodies play a significant role in the pathogenesis or progression of Parkinson disease e.g. to Parkinson disease with dementia, while NMDA IgG antibodies define a separate disease of its own.
- 15 April 2014
- Published by Wiley in Movement Disorders
- Vol. 29 (5) , 622-633
What can biomarkers tell us about cognition in Parkinson's disease?
Cognitive decline is common in Parkinson's disease (PD), even in the early motor stage, and this non‐motor feature impacts quality of life and prognosis tremendously. In this article, we discuss marker candidates for cognitive decline in PD from different angles, including functional and structural imaging techniques, biological fluid markers in cerebrospinal fluid, and blood genetic predictors, as well as gait as a surrogate marker of cognitive decline. Specifically, imaging‐based markers of cognitive impairment in PD include cortical atrophy, reduced cortical metabolism, loss of cortical cholinergic and frontal dopaminergic function, as well as an increased cortical amyloid load. Reduced β‐amyloid(1‐42) in cerebrospinal fluid and lower plasma levels of epidermal growth factor are predictors for cognitive decline in PD. In addition, genetic variation in the apolipoprotein E (APOE), catechol‐O‐methyltransferase (COMT), microtubule‐associated protein tau (MAPT), and glucocerebrosidase (GBA) genes may confer risk for cognitive impairment in PD; and gait disturbance may also indicate an increased risk for dementia. Other marker candidates have been proposed and are discussed. All of the current studies are hampered by gaps in our knowledge about the molecular causes of cognitive decline, which will have to be considered in future biomarker studies. © 2014 International Parkinson and Movement Disorder Society
- 15 April 2014
- Published by Wiley in Movement Disorders
- Vol. 29 (5) , 622-633
What can biomarkers tell us about cognition in Parkinson's disease?
Cognitive decline is common in Parkinson's disease (PD), even in the early motor stage, and this non‐motor feature impacts quality of life and prognosis tremendously. In this article, we discuss marker candidates for cognitive decline in PD from different angles, including functional and structural imaging techniques, biological fluid markers in cerebrospinal fluid, and blood genetic predictors, as well as gait as a surrogate marker of cognitive decline. Specifically, imaging‐based markers of cognitive impairment in PD include cortical atrophy, reduced cortical metabolism, loss of cortical cholinergic and frontal dopaminergic function, as well as an increased cortical amyloid load. Reduced β‐amyloid(1‐42) in cerebrospinal fluid and lower plasma levels of epidermal growth factor are predictors for cognitive decline in PD. In addition, genetic variation in the apolipoprotein E (APOE), catechol‐O‐methyltransferase (COMT), microtubule‐associated protein tau (MAPT), and glucocerebrosidase (GBA) genes may confer risk for cognitive impairment in PD; and gait disturbance may also indicate an increased risk for dementia. Other marker candidates have been proposed and are discussed. All of the current studies are hampered by gaps in our knowledge about the molecular causes of cognitive decline, which will have to be considered in future biomarker studies. © 2014 International Parkinson and Movement Disorder Society
- 1 January 2014
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 20, S76-S79
Quantification of α-synuclein in cerebrospinal fluid: How ideal is this biomarker for Parkinson's disease?
- 1 January 2014
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 20, S76-S79
Quantification of α-synuclein in cerebrospinal fluid: How ideal is this biomarker for Parkinson's disease?
- 7 July 2013
- Published by Springer Nature in Der Nervenarzt
- Vol. 84 (8) , 918-926
Früherkennung der Parkinson-Krankheit
- 7 July 2013
- Published by Springer Nature in Der Nervenarzt
- Vol. 84 (8) , 918-926
Früherkennung der Parkinson-Krankheit
- 1 January 2013
- Published by Elsevier in Neuroscience Letters
- Vol. 532, 44-48
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
- 1 January 2013
- Published by Elsevier in Neuroscience Letters
- Vol. 532, 44-48
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
- 18 July 2012
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 26 (4) , 238-245
Plasma Amyloid-BetaPeptides in Acute Cerebral Ischemia: A Pilot Study
Blood-based tests for a rapid and valid diagnosis as well as outcome prognosis of acute stroke are desirable. Recently, plasma Aβ40 was suggested as an independent cerebrovascular risk factor candidate. We investigated eight plasma samples of patients with clinical signs of acute cerebral ischemia for derangements of plasma amyloid-beta (Aβ) peptide patterns as compared to 13 patients with other neuropsychiatric diseases. For the analysis of plasma, we used immunoprecipitation followed by the quantitative Aβ-SDS-PAGE/immunoblot. The major outcome was a striking decrease of Aβ1-40 in plasma paralleled by an increase in the ratio of Aβ1-38/Aβ1-40 in two patients with acute stroke. Interestingly, these patients had an onset of symptoms within only 2-4 hr before venous puncture and there was a strong correlation of Aβ1-38/Aβ1-40 levels with the time span between onset of symptoms and venous puncture. From these results, we suggest the ratio of plasma Aβ1-38/Aβ1-40 as a possible biomarker for the early diagnosis of acute stroke.
- 18 July 2012
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 26 (4) , 238-245
Plasma Amyloid-BetaPeptides in Acute Cerebral Ischemia: A Pilot Study
Blood-based tests for a rapid and valid diagnosis as well as outcome prognosis of acute stroke are desirable. Recently, plasma Aβ40 was suggested as an independent cerebrovascular risk factor candidate. We investigated eight plasma samples of patients with clinical signs of acute cerebral ischemia for derangements of plasma amyloid-beta (Aβ) peptide patterns as compared to 13 patients with other neuropsychiatric diseases. For the analysis of plasma, we used immunoprecipitation followed by the quantitative Aβ-SDS-PAGE/immunoblot. The major outcome was a striking decrease of Aβ1-40 in plasma paralleled by an increase in the ratio of Aβ1-38/Aβ1-40 in two patients with acute stroke. Interestingly, these patients had an onset of symptoms within only 2-4 hr before venous puncture and there was a strong correlation of Aβ1-38/Aβ1-40 levels with the time span between onset of symptoms and venous puncture. From these results, we suggest the ratio of plasma Aβ1-38/Aβ1-40 as a possible biomarker for the early diagnosis of acute stroke.
- Open Access
- 18 March 2012
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 119 (7) , 739-746
α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system
The source of Parkinson disease-linked α-synuclein (aSyn) in human cerebrospinal fluid (CSF) remains unknown. We decided to measure the concentration of aSyn and its gradient in human CSF specimens and compared it with serum to explore its origin. We correlated aSyn concentrations in CSF versus serum (QaSyn) to the albumin quotient (Qalbumin) to evaluate its relation to blood–CSF barrier function. We also compared aSyn with several other CSF constituents of either central or peripheral sources (or both) including albumin, neuron-specific enolase, β-trace protein and total protein content. Finally, we examined whether aSyn is present within the structures of the choroid plexus (CP). We observed that QaSyn did not rise or fall with Qalbumin values, a relative measure of blood–CSF barrier integrity. In our CSF gradient analyses, aSyn levels decreased slightly from rostral to caudal fractions, in parallel to the recorded changes for neuron-specific enolase; the opposite trend was recorded for total protein, albumin and β-trace protein. The latter showed higher concentrations in caudal CSF fractions due to the diffusion-mediated transfer of proteins from blood and leptomeninges into CSF in the lower regions of the spine. In postmortem sections of human brain, we detected highly variable aSyn reactivity within the epithelial cell layer of CP in patients diagnosed with a range of neurological diseases; however, in sections of mice that express only human SNCA alleles (and in those without any Snca gene expression), we detected no aSyn signal in the epithelial cells of the CP. We conclude from these complementary results that despite its higher levels in peripheral blood products, neurons of the brain and spinal cord represent the principal source of aSyn in human CSF.
- 18 March 2012
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 119 (7) , 739-746
Open Accessα-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system
The source of Parkinson disease-linked α-synuclein (aSyn) in human cerebrospinal fluid (CSF) remains unknown. We decided to measure the concentration of aSyn and its gradient in human CSF specimens and compared it with serum to explore its origin. We correlated aSyn concentrations in CSF versus serum (QaSyn) to the albumin quotient (Qalbumin) to evaluate its relation to blood–CSF barrier function. We also compared aSyn with several other CSF constituents of either central or peripheral sources (or both) including albumin, neuron-specific enolase, β-trace protein and total protein content. Finally, we examined whether aSyn is present within the structures of the choroid plexus (CP). We observed that QaSyn did not rise or fall with Qalbumin values, a relative measure of blood–CSF barrier integrity. In our CSF gradient analyses, aSyn levels decreased slightly from rostral to caudal fractions, in parallel to the recorded changes for neuron-specific enolase; the opposite trend was recorded for total protein, albumin and β-trace protein. The latter showed higher concentrations in caudal CSF fractions due to the diffusion-mediated transfer of proteins from blood and leptomeninges into CSF in the lower regions of the spine. In postmortem sections of human brain, we detected highly variable aSyn reactivity within the epithelial cell layer of CP in patients diagnosed with a range of neurological diseases; however, in sections of mice that express only human SNCA alleles (and in those without any Snca gene expression), we detected no aSyn signal in the epithelial cells of the CP. We conclude from these complementary results that despite its higher levels in peripheral blood products, neurons of the brain and spinal cord represent the principal source of aSyn in human CSF.
- Open Access
- 15 June 2011
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 118 (8) , 1261-1262
Erratum to: Different CSF β-amyloid processing in Alzheimer’s and Creutzfeldt–Jakob disease
- 15 June 2011
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 118 (8) , 1261-1262
Open AccessErratum to: Different CSF β-amyloid processing in Alzheimer’s and Creutzfeldt–Jakob disease
- 11 April 2011
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 24 (2) , 383-391
CSF Amyloid-β Peptides in Neuropathologically Diagnosed Dementia with Lewy Bodies and Alzheimer's Disease
Appropriate treatment of dementia requires biomarkers that provide an exact and differential diagnosis. We recently presented differentially expressed amyloid-β (Aβ) peptide patterns in cerebrospinal fluid (CSF) as biomarker candidates for neurochemi
- 11 April 2011
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 24 (2) , 383-391
CSF Amyloid-β Peptides in Neuropathologically Diagnosed Dementia with Lewy Bodies and Alzheimer's Disease
Appropriate treatment of dementia requires biomarkers that provide an exact and differential diagnosis. We recently presented differentially expressed amyloid-β (Aβ) peptide patterns in cerebrospinal fluid (CSF) as biomarker candidates for neurochemi
- 1 March 2011
- Published by Elsevier in The Lancet Neurology
- Vol. 10 (3) , 230-240
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
- 1 March 2011
- Published by Elsevier in The Lancet Neurology
- Vol. 10 (3) , 230-240
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study